impact factor
logo
 

Clinical aspects

 

Serum CXCL13, BAFF, IL-21 and IL-22 levels are related to disease activity and lymphocyte profile in primary Sjögren’s syndrome


1, 2, 3, 4, 5, 6

 

  1. Autoimmune Systemic Diseases Unit, Internal Medicine Department, Hospital Universitari Vall d’Hebron, Barcelona, and Department of Medicine, Faculty of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  2. Immunology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  3. Immunology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  4. Flow Cytometry Unit, Haematology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain.
  5. Autoimmune Systemic Diseases Unit, Internal Medicine Department, Hospital Universitari Vall d’Hebron, Barcelona, and Department of Medicine, Faculty of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  6. Autoimmune Systemic Diseases Unit, Internal Medicine Department, Hospital Universitari Vall d’Hebron, Barcelona, and Department of Medicine, Faculty of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. rsolanslaq@gmail.com

CER15206
2021 Vol.39, N°6 ,Suppl.133
PI 0131, PF 0139
Clinical aspects

Free to view
(click on article PDF icon to read the article)

PMID: 34919042 [PubMed]

Received: 01/10/2021
Accepted : 23/11/2021
In Press: 15/12/2021
Published: 15/12/2021

Abstract

OBJECTIVES:
To investigate the utility of serum BAFF, IL-17, IL-18, IL-21, IL-22, CXCL13, TNF-R2 and PD-L2 as biomarkers of disease activity in primary Sjögren’s syndrome (pSS), their relationship with lymphocyte subpopulations and their accuracy to discriminate pSS from Sicca syndrome.
METHODS:
We conducted an observational study on 66 pSS patients and 48 controls (25 with Sicca syndrome and 23 healthy volunteers). Serum levels of BAFF, IL-17 A/F, IL-18, IL-21, IL-22, CXCL13, TNF-R2 and PD-L2 were measured using a multiplex immunoassay. Lymphocyte subpopulations were analysed by flow cytometry. Disease activity of pSS was assessed with ESSDAI at study inclusion.
RESULTS:
Patients with pSS presented higher serum CXCL13 (364.7 vs. 205.2 pg/mL), IL-21 (43.2 vs. 0 pg/mL) and BAFF (1646 vs. 1369 pg/mL), and lower PD-L2 levels (1950.8 vs. 2792.3 pg/mL) than controls. ESSDAI was associated with BAFF, IL-18 and IL-22. Patients with ESSDAI >0 exhibited higher CXCL13, IL-21, IL-22 and TNFR2 concentrations. IL-21 levels correlated with lower memory B-cell and higher naïve B-cell percentages and IL-22 levels correlated with increased circulating activated CD4+ T-cells. The combination of serum CXCL13, BAFF and PDL2 levels using the formula [ln(CXCL13)+ln(BAFF)]/ln(PDL2) exhibit an AUC of 0.854 (95% CI: 0.750-0.919) to discriminate between pSS and Sicca syndrome (sensitivity 77.2% and specificity 86.4% using a cut-off of 1.7).
CONCLUSIONS:
CXCL13, BAFF, IL-21, and IL-22 are potential biomarkers of pSS activity and IL-21 and IL-22 are associated with disturbances of lymphocyte subpopulations in pSS. The combination of serum CXCL13, BAFF, and PD-L2 levels allows discrimination between pSS and Sicca syndrome.

DOI: https://doi.org/10.55563/clinexprheumatol/fp741f

Rheumatology Article